20:01 , Feb 5, 2019 |  BC Extra  |  Politics & Policy

Senators push pharma CEOs on drug prices

Inquiries from Congress continue to pile up with a growing focus on rising costs of insulin, as senators press pharmaceutical companies yet again to disclose drug pricing information. Senate Health, Education, Labor and Pensions (HELP)...
00:35 , Feb 1, 2019 |  BC Innovations  |  Tools & Techniques

TMB needs company

Tumor mutation burden is looking less like a magic bullet and more like just one of at least three variables that could jointly predict responses to checkpoint inhibitors. Combining TMB measurements with markers of T...
21:22 , Jan 18, 2019 |  BioCentury  |  Politics, Policy & Law

Pharma falling off budget cliff

Three strong arms are lining up in Washington to take turns whacking the biopharma piñata. Divisions within the industry, a lack of new ideas, and resistance to change are making a bad situation worse for...
21:17 , Dec 14, 2018 |  BC Week In Review  |  Company News

Veteran Roche cancer executive O'Day to lead Gilead

Daniel O’Day will inherit a pile of cash and a company that is looking beyond infectious disease to carve out its space in cancer and build on its newly acquired CAR T platform when he...
20:23 , Dec 10, 2018 |  BC Extra  |  Company News

Veteran Roche cancer executive O'Day to lead Gilead

Daniel O’Day will inherit a pile of cash and a company that is looking beyond infectious disease to carve out its space in cancer and build on its newly acquired CAR T platform when he...
23:53 , Nov 30, 2018 |  BC Extra  |  Clinical News

Trial registry shows He targeting PCSK9 in human embryos

Chinese scientist Jiankui He is conducting a second germline gene editing trial using CRISPR to target PCSK9 in human embryos, according to a retrospective clinical trial listing on the Chinese clinical trial registry. Chinese researchers...
00:25 , Nov 30, 2018 |  BC Extra  |  Politics & Policy

Summit committee issues call to define path to clinical germline editing

The organizing committee of the Second International Summit on Human Genome Editing said the time has come to define "a rigorous, responsible translational pathway" towards the clinical practice of germline editing. The pathway should include...
22:09 , Nov 28, 2018 |  BC Extra  |  Clinical News

Critics continue to pile on as CRISPR researcher describes informed consent, review process

Jiankui He outlined the peer review and informed consent process used in the first-ever human CRISPR germline gene editing trial at the International Summit on Human Genome Editing on Wednesday. However, critics decried the process...
01:37 , Aug 10, 2018 |  BC Innovations  |  Finance

Super-sized ambitions

A trend toward super-sized initial financings is attracting a new set of deep-pocketed investors to the early stage space. These new players are making earlier commitments with hopes of guaranteeing larger ownership positions at an...
03:02 , Jun 30, 2018 |  BioCentury  |  Finance

Smitten by SMID-caps

Risk is pervasive heading into the third quarter and choppy waters are expected, but 13 buysiders told BioCentury they’re not afraid to stay the course. A politically charged environment is likely to intensify as the...